On October 14, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced via Access Newswire that its lead candidate Telomir‑1 demonstrated cytotoxic activity against aggressive pancreatic cancer cells in new laboratory studies. The announcement, made in Miami, Florida, follows the company’s prior preclinical successes in triple‑negative breast cancer and prostate cancer models. The data confirm that Telomir‑1 consistently disrupts cancer cell survival pathways across multiple tumor types.
Pancreatic cancer is among the most lethal malignancies, with limited effective treatment options. By showing activity in this disease, Telomir expands the potential therapeutic scope of Telomir‑1 beyond its earlier indications, strengthening the company’s pipeline and positioning it for broader clinical development. The new findings also reinforce the platform’s mechanistic rationale of targeting epigenetic drivers of cancer and aging.
The release of these preclinical results is a key milestone that may support future IND filing and attract strategic interest from investors and potential partners. While the data are still at the laboratory stage, they provide a compelling foundation for advancing Telomir‑1 toward human trials and underscore the company’s progress in addressing high‑need oncology indications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.